✨ Free AI Report
InspireMD, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research InspireMD, Inc.
Company Research

InspireMD, Inc.: Business Overview, Financials & Competitive Analysis

InspireMD, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). InspireMD presents a commercialization inflection story with FDA-approved carotid stent technology, but investor confidence hinges on revenue ramp-up and path to profitability in 2026-2027. The company is operating at a net loss of -$32 million on trailing twelve months basis, while having achieved FDA approval and commercial launch of its.

What is InspireMD, Inc.'s industry? InspireMD, Inc. (inspiremd.com) operates in Medical Devices - Cardiovascular Intervention & Stroke Prevention. AskCyborg classifies InspireMD, Inc. under Medical Devices - Cardiovascular Intervention & Stroke Prevention in its company registry.

InspireMD is a medical device company focused on developing and commercializing products for treating carotid artery and other vascular diseases across Europe, Latin America, the Middle East, and Asia Pacific. The com...

4/ 10Mixed

Cyborg Score thesis

InspireMD presents a commercialization inflection story with FDA-approved carotid stent technology, but investor confidence...

Read the full analyst-debate transcript →
Industry Medical Devices - Cardiovascular Intervention & Stroke Prevention
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest InspireMD, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for InspireMD, Inc.

AskCyborg analysts argue the bull and bear cases for InspireMD, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
InspireMD, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

InspireMD, Inc. Overview

Pro stress-test →

InspireMD is a medical device company focused on developing and commercializing products for treating carotid artery and other vascular diseases across Europe, Latin America, the Middle East, and Asia Pacific. The company's flagship product, CGuard Prime carotid stent system, received FDA approval and was commercially launched in the U.S. on July 9, 2025, marking a significant milestone in its evolution.

Strategic Profile

Pro stress-test →

The company's MicroNet stent technology integrates a self-expandable nitinol stent with an innovative mesh structure designed to reduce embolic events during carotid interventions, enhancing both immediate and long-term patient outcomes. InspireMD's business model revolves around direct sales of innovative stent systems, and the company has streamlined manufacturing and enhanced operational capabilities in strategic regions, with its new U.S. headquarters established to strengthen commercial infrastructure.

Competitive Landscape

Pro stress-test →

InspireMD distinguishes itself through specialized focus on carotid stenting systems, cultivating a niche by addressing unmet needs in carotid artery disease management through state-of-the-art technology with clinical validation. Primary competitors in carotid stent market include Abbott Vascular, Boston Scientific, and Medtronic, though InspireMD's MicroNet embolic protection technology offers differentiated positioning.

Industry Context

InspireMD, Inc. operates in Medical Devices - Cardiovascular Intervention & Stroke Prevention.

Key facts

Headquarters: Miami, Florida, USA · Revenue: $7.0M · Market cap: $88.6M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on InspireMD, Inc..

  • FDA approval and U.S. commercial launch of CGuard Prime in July 2025 represents critical inflection point for revenue growth
  • Company secured $58 million in combined financing (PIPE and warrant exercises) in late 2024 to fund U.S. launch and operations
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • July 2025Official commercial launch of CGuard Prime carotid stent system in U.S. following FDA approval
  • December 2024First patient enrolled in CGUARDIANS II pivotal study for CGuard Prime in TCAR procedures
  • +2 moreTrack every material event for InspireMD, Inc. as it happens. Explore monitoring →
Get alerted when InspireMD, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Embolic Prevention DevicesLeading carotid stent platform with extensive market share in North America→Carotid Artery StentsEstablished player with comprehensive vascular intervention portfolio→Vascular Intervention SystemsLarge diversified medical device company with competing stroke prevention solutions→

Compare InspireMD, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

InspireMD, Inc. operates in Medical Devices - Cardiovascular Intervention & Stroke Prevention. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Devices - Cardiovascular Intervention & Stroke Prevention research →
NEW · MCP server

Ask your AI assistant about InspireMD, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare InspireMD, Inc. and its top competitor on Cyborg Score”
“What did InspireMD, Inc. do this quarter?”
“Is InspireMD, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does InspireMD, Inc. do?+
InspireMD is a medical device company focused on developing and commercializing products for treating carotid artery and other vascular diseases across Europe, Latin America, the Middle East, and Asia Pacific. The com...
What is InspireMD, Inc.'s Cyborg Score?+
InspireMD, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are InspireMD, Inc.'s main competitors?+
Named competitors include Embolic Prevention Devices, Carotid Artery Stents, Vascular Intervention Systems. The full competitive landscape is in the AskCyborg report.
How can I get the full InspireMD, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the InspireMD, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track InspireMD, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.